Galmed stock: buy or sell?
December 6th, 2019
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.
Should I buy Galmed stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Following a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Galmed Pharmaceuticals stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Galmed Pharmaceuticals stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we gathered 6 ratings published for GLMD stock in the last month. The general sentiment of these ratings is bullish for GLMD stock, with 6 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
Galmed stock analysis
Galmed closed today at $6.50 and slightly fell a fatal -1.66%.
Galmed shares slightly fell -1.66% to $6.50 today. Since price and SMA200d lines crossed up on December/4, GLMD climbed $0.80 (14.04%). From a daily perspective, GLMD is in a short term uptrend after plotting its last bottom ($4.38, on November 27th) higher than the previous bottom, and its last top ($7.38, on Dec/4) also over the previous top. Now trading in between its last bottom and last top GLMD might consolidate in a plain range, waiting to break out over $7.38 or down under $4.38.
Galmed broke up the simple moving average line of 200d, closing at $6.50. Early November GLMD plummed a spooky -8.31% in just one week.
Galmed stock price history
Galmed IPO was on March 13th, 2014 at $17.00 per share1. Since then, GLMD stock lost a -61.80%, with a yearly average of -12.40%.
1: Adjusted price after possible price splits or reverse-splits.
Galmed stock historical price chart
GLMD stock reached 52-week highs on December at $9.74, and all-time highs 2018-06-12 with a price of 27.06.
Galmed stock price target is $46.00Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We have 3 price targets for Galmed Pharmaceuticals stock posted in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Galmed Pharmaceuticals presented its financial report, posting an exceptional climb for the Earnings per Share (EPS) ratio. Analyst expected $-0.12 per share, but Galmed posted $-0.19.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual turnover report draw a dazzling growth of 87.83% to $2.04 M dollars. In the same way, its profit margin (compared to sales) climbed to -483.61%, that is $-9.86 million.
|2016||$0.47 M||-||$-16.95 M-3630.2%||-|
|2017||$1.09 M||132.33%||$-12.30 M-1133.5%||-27.45%|
|2018||$2.04 M||87.83%||$-9.86 M-483.6%||-19.86%|
Quarterly financial resultsGalmed Pharmaceuticals posted $0.00 million in revenues for 2018-Q4, a -100.00% less compared to previous quarter. Reported quarter income marked $-3.71 M with a profit margin of . Profit margin stayed constant a 0.00% compared to previous quarter when profit margin was -63.93%. When comparing revenues to same quarter last year, Galmed sales marked a hair-raising loss and collapsed a -100.00%.
|2017-Q1||$0.27 M||-||$-3.16 M-1179.1%||-|
|2017-Q2||$0.27 M||0.75%||$-2.69 M-996.3%||-14.87%|
|2017-Q3||$0.27 M||1.11%||$-2.80 M-1025.6%||4.09%|
|2017-Q4||$0.27 M||0.37%||$-3.64 M-1329.9%||30.14%|
|2018-Q1||$0.27 M||-2.19%||$-2.51 M-935.1%||-31.23%|
|2018-Q2||$0.27 M||0.75%||$-2.69 M-994.4%||7.14%|
|2018-Q3||$1.50 M||455.56%||$-0.96 M-63.9%||-64.28%|
Galmed ownershipWhen you are planning to invest in shares of a stock, it's always worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Galmed Pharmaceuticals, 21.13% of all outstanding shares are owned by its staff.
In case of Galmed stock, 37.70% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for GLMD stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related companies:
|Market cap||$137.3 M||$39.0 M||$25.3 M||$183.1 M|
|Total shares||21.1 M||24.2 M||3.6 M||61.3 M|
|Float shares||13.6 M||21.2 M||2.0 M||39.5 M|
|- Institutional holdings (%)||37.7%||30.3%||49.4%||291.2%|
|- Insider holdings (%)||21.1%||5.7%||14.6%||0.7%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%|
|Friday, December 6th, 2019|
|Day range||$5.80 - $6.77|
|Average true range||$0.55|
|50d mov avg||$4.43|
|100d mov avg||$4.87|
|200d mov avg||$6.14|
Galmed performanceTo measure stock performance is always good to compare with competitors or related stocks. We compared Galmed against Evoke Pharma, Eyegate Pharmaceuticals and Foamix Pharmaceuticals in the following table: